Paola Di Carlo Selected Research

Paola Di Carlo Research Topics

Disease

13	Infections 06/2023 - 06/2005
12	Tuberculosis (Tuberculoses) 11/2023 - 12/2002
3	Neoplasms (Cancer) 01/2024 - 01/2013
3	Coinfection 01/2020 - 01/2014
3	HIV Infections (HIV Infection) 01/2020 - 09/2006
3	Communicable Diseases (Infectious Diseases) 12/2019 - 01/2017
3	Osteoporosis 01/2015 - 08/2012
2	Acquired Immunodeficiency Syndrome (AIDS) 11/2023 - 01/2014
2	Staphylococcal Infections 06/2023 - 03/2015
2	Sepsis (Septicemia) 06/2023 - 08/2022
2	Latent Infection 01/2018 - 01/2009
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2015 - 11/2010
2	Lipodystrophy 09/2013 - 05/2012
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2013 - 05/2012
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024
1	Burkitt Lymphoma (Burkitt's Lymphoma) 11/2023
1	Cytomegalovirus Infections (Inclusion Disease) 11/2023
1	Hepatitis B 11/2023
1	Skin Manifestations 11/2023
1	Syphilis 11/2023
1	Toxoplasmosis 11/2023
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 07/2023
1	Reinfection 06/2023
1	Latent Tuberculosis 01/2023
1	Fever (Fevers) 11/2022
1	Venous Thromboembolism 08/2022
1	Disseminated Intravascular Coagulation 08/2022
1	Enterocolitis 08/2022
1	Cross Infection (Nosocomial Infection) 08/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 08/2022
1	Primary Myelofibrosis (Myelosclerosis) 02/2022
1	Polycythemia Vera 02/2022
1	Essential Thrombocythemia 02/2022
1	Thrombosis (Thrombus) 02/2022
1	Disease Progression 01/2022
1	Malaria 01/2020
1	Meningitis 01/2020
1	Chronic Hepatitis C 04/2019
1	Visceral Leishmaniasis (Kala Azar) 04/2019
1	Leishmaniasis 04/2019
1	Inflammation (Inflammations) 04/2019
1	Stomach Diseases 01/2019
1	Epstein-Barr Virus Infections 01/2019
1	Lung Diseases (Lung Disease) 01/2018
1	Acute Abdomen 07/2017
1	Hypertension (High Blood Pressure) 01/2016

Drug/Important Bio-Agent (IBA)

8	Anti-Bacterial Agents (Antibiotics)IBA 01/2024 - 09/2011
3	AntigensIBA 01/2020 - 01/2018
3	Tuberculin (PPD)IBA 01/2018 - 12/2002
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 12/2002
2	C-Reactive ProteinIBA 11/2022 - 02/2022
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 01/2020
2	AntibodiesIBA 01/2021 - 03/2008
2	Immunoglobulin M (IgM)IBA 01/2021 - 03/2008
2	Vitamin D FDA LinkGeneric 01/2020 - 01/2015
2	Interleukin-10 (Interleukin 10)IBA 01/2019 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2014
2	CytokinesIBA 01/2018 - 04/2015
2	carbapenemaseIBA 10/2014 - 09/2011
2	Triglycerides (Triacylglycerol)IBA 09/2013 - 05/2012
2	CholesterolIBA 09/2013 - 05/2012
1	erucylphosphocholineIBA 01/2024
1	bictegravirIBA 11/2023
1	Penicillins (Penicillin)FDA Link 11/2023
1	Azithromycin (Zithromax)FDA LinkGeneric 07/2023
1	Ciprofloxacin (Cipro)FDA LinkGeneric 07/2023
1	mRNA VaccinesIBA 06/2023
1	VaccinesIBA 06/2023
1	Messenger RNA (mRNA)IBA 06/2023
1	CoagulaseIBA 06/2023
1	Oxacillin (Prostaphlin)FDA LinkGeneric 06/2023
1	BCG Vaccine FDA Link 01/2023
1	chlorambucil-docosahexaenoic acid conjugateIBA 08/2022
1	Dacarbazine (DIC)FDA LinkGeneric 08/2022
1	PyrinIBA 08/2022
1	InflammasomesIBA 08/2022
1	Hydroxyurea (Hydrea)FDA LinkGeneric 02/2022
1	AnticoagulantsIBA 02/2022
1	ruxolitinibIBA 02/2022
1	Immunoglobulin A (IgA)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	GoldIBA 01/2021
1	NivolumabIBA 01/2020
1	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	AerosolsIBA 01/2020
1	Programmed Cell Death 1 ReceptorIBA 01/2020
1	Hazardous Substances (Hazardous Materials)IBA 12/2019
1	Antiviral Agents (Antivirals)IBA 04/2019
1	SofosbuvirIBA 04/2019
1	Ribavirin (Virazole)FDA LinkGeneric 04/2019
1	QuinolonesIBA 01/2019
1	AminoglycosidesIBA 01/2019
1	Peptides (Polypeptides)IBA 04/2015

Therapy/Procedure

16	Therapeutics 11/2023 - 06/2005
3	Drug Therapy (Chemotherapy) 01/2023 - 07/2007
2	Art Therapy 09/2019 - 01/2014
1	Length of Stay 11/2023
1	Patient Admission (Patient Admissions) 11/2023
1	Intradermal Injections 01/2018